静脉溶栓联合依拉达奉治疗急性脑梗死的临床评价

目的探讨静脉溶栓联合依拉达奉治疗急性脑梗死的安全性和有效性。方法：选取急性脑梗死患者78例，随机分为对照组和观察组，在给予基础治疗的基础上，两组均给予尿激酶静脉滴注溶栓治疗，溶栓后，观察组继续给予依达拉奉治疗。结果：两组治疗后7、14、21 d的ADL、ESS评分，14、21 d两组NIHSS评分存在统计学意义（P〈0．05）；总有效率比较，对照组为76．9％，观察组为89．7％，差异有统计学意义（P〈0．05）；在观察期，观察组39例没有不良反应产生。结论：研究表明静脉溶栓联合依达拉奉治疗急性脑梗死，疗效显著。

Objective To evaluate the safety and effect of the treatment for acute cerebral infarction by Intravenous Thrombolysis combinedwith Edaravone.Methods：A total of 78 ACI patients who were conform to the requirements of the group were randomly divided into control groupand observation group,two groups were treated with basic therapy,all thrombolytic treated with UK through Intravenous injection, afterthrombolytie therapy,the observation group were continue treated with edarvone.Results：Afler therapy for 7,14,21 days,the ADL,ESS scoreshad statistically significant differences （P〈0.05）between two groups, the same as the NIHSS scores after therapy for 14-21 days;The totaleffective rate of the control group was 76.9%,significantly lower than 89.7% of the observation group;during the experimental period,the 39patients of the observation group had no adverse reaction.Conclusions：The therapy of Intravenous Thrombolysis combined with edarvone hassignifieantclinical effect and high safety.